Estrogen, Progestrone Receptor and Her2/Neu Expressions incases of Breast Cancer

Mahendra M Patil; Pawar S J; Rohit S Kadam; Atul B Hulwan; Mahendra Alate; Dhirajkumar Mane

doi:10.26452/ijrps.v13i2.181

Mahendra M Patil ⁽¹⁾ , Pawar S J ⁽²⁾ , Rohit S Kadam ⁽³⁾ , Atul B Hulwan ⁽⁴⁾ , Mahendra Alate ⁽⁵⁾ , Dhirajkumar Mane ⁽⁶⁾

(1) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India ,

(2) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India ,

(3) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India ,

(4) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India ,

(5) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India ,

(6) Department of Pathology, Krishna Institute of Medical Sciences, Karad-415539, Maharashtra, India, India

https://doi.org/10.26452/ijrps.v13i2.181

Issue
Vol. 13 No. 2 (2022): Volume 13 Issue 2

Keywords:

Breast cancer, Estrogen receptors, Invasive ductal carcinoma, Progesterone receptor, Hormone receptor

PDF LaTeX HTML ePUB

Abstract

To correlate ER, PR and HER2/neu expressions with established prognostic factors viz. type of tumour, tumour size, tumour grade, tumour necrosis, lymphovascular invasion (tumor emboli), and axillary lymph node metastasis status. To correlate immunehistochemical marker status ( ER, PR and HER2/neu) with clinical details (age and sex) of patients. The investigative research of Progesterone receptor (PR), Estrogen receptor (ER), as well as HER-2/neu expressions in cases of developing breast carcinoma was carried out over a period of 2 years from June 2015 to May 2017 which included 101 breast cancer cases. Palpable breast lump with or without pain were most frequent complaints. Maximum number of breast cancer cases revealed involvement of left breast. It was found that ER and PR expression was strongly correlated. No significant association was found between the presence of ER, PR expression as well as the size of the tumor. ER and PR negativity was associated with breast carcinoma cases having axillary lymph node metastasis. Out of 101 breast cancer cases tumor necrosis was present in 38.61%. However, the occurrence or absence of tumour necrosis in ER, PR expression was not strongly linked. Tumor emboli were noted in 31.68% of cases. In case of breast cancer with tumor emboli decreased ER and PR expression was observed.

Full text article

Generated from XML file

References

V M Bhagat, B M Jha, and P R Patel. Correlation of hormonal receptor and Her-2/neu expression in breast cancer: a study at tertiary care hospital in south Gujarat. Natl J Med Res, 2(3):295–303, 2012.

Stanley P. L. Leong, Zhen-Zhou Shen, Tse-Jia Liu, Gaurav Agarwal, Tomoo Tajima, Nam-Sun Paik, Kerstin Sandelin, Anna Derossis, Hiram Cody, and William D. Foulkes. Is Breast Cancer the Same Disease in Asian and Western Countries? World Journal of Surgery, 34(10):2308– 2324, 2010.

P Shrigondekar, S Desai, S Bhosale, D Mankar, and A Badwe. Study of Hormone Receptor Status of Breast Carcinoma and Its Correlation with the Established Prognostic Markers. Research Gate, 1(2):109–116, 2020.

S A Hoda. Invasive ductal carcinoma: assessment of prognosis with morphologic and bio- logic markers, Rosen’s breast pathology, 4th edn. Philadelphia, USA, 413, 2014. Lippincott Williams & Wilkins.

L Biganzoli, M Castiglione, and M J Piccart. Adjuvant Therapy for Breast Cancer. volume 151, pages 13–30. Springer-Verlag US, 2009.

David L. Page, Ian O. Ellis, and Christopher W. Elston. Histologic Grading of Breast Cancer: Let’s Do It. American Journal of Clinical Pathology, 103(2):123–124, 1995.

V. Le Doussal, M. Tubiana-Hulin, S. Friedman, K. Hacene, F. Spyratos, and M. Brunet. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multi- variate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64(9):1914–1921, 1989.

Jay R. Harris, Marc E. Lippman, Monica Morrow, et al. Diseases of the breast: Fifth edition. pages 1–3. Wolters Kluwer Health Adis (ESP), 2014.

W. J. King and G. L. Greene. Monoclonal anti- bodies localize oestrogen receptor in the nuclei of target cells. Nature, 307(5953):745–747, 1984.

W C Willett, R Tamimi, S E Hankinson, A Hazra, A Eliassen, and G Colditz. Nongenetic factors in the causation of breast cancer. Research Gate, pages 221–253, 2014.

Martin L. Lesser, Paul Peter Rosen, Ruby T. Senie, Kathleen Duthie, Celia Menendez-Botet, and Morton K. Schwartz. Estrogen and progesterone receptors in breast carcinoma: Correlations with epidemiology and pathology. Cancer, 48(2):299–309, 1981.

Kenneth S. McCarty, Thomas K. Barton, Bernard F. Fetter, Brett H. Woodard, Jeffrey A. Mossler, William Reeves, John Daly, William E. Wilkinson, and Kenneth S. McCarty. Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer, 46(S12):2851–2858, 1980.

S. E. Pinder, S. Murray, I. O. Ellis, et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer, 83(8):1529–1539, 1998.